Development of a serum-based microRNA panel for Alzheimer's disease diagnosis
Journal of Translational Internal Medicine · 25.06.2026 · 14 (3) · 456-469
DOI: 10.1515/jtim-2026-0038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Translational Internal Medicine, online erschienen am 13.06.2026. Verfasst von Qi Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background and Objectives MicroRNAs (miRNAs) are emerging as promising blood-based biomarkers for Alzheimer's disease (AD) because of their stability and regulatory roles in disease-related pathways. This study aimed to develop a serum-based miRNA panel for AD diagnosis.
Methods
Serum samples from 550 participants were categorized into discovery (85 AD, 65 healthy controls [HCs]), training (73 AD, 53 HCs), and validation (99 AD, 99 HCs, 36 vascular cognitive impairment [VCI], 40 dementia with Lewy bodies [DLB]) cohorts. Through small RNA sequencing and qPCR validation, we identified key miRNAs and constructed a diagnostic panel via machine learning.
Results
The 7-miRNA panel achieved area under the curve (AUC) values of 0.970 and 0.928 in the training and validation cohorts, respectively. The panel effectively differentiated AD from VCI (AUC = 0.951) and DLB (AUC = 0.851). Diagnostic performance remained robust across subgroups defined by age, gender, disease severity, and comorbidities (AUC 0.758–0.988). The risk score derived from the 7-miRNA panel was significantly associated with cognitive impairment (Mini-Mental State Examination [MMSE] score, r = -0.72) and plasma amyloid pathology biomarkers (Aβ42/40 ratio, r = -0.25; p-tau217, r = 0.36).
Conclusions
A serum-based 7-miRNA panel, which offers a minimally invasive and accessible approach, has strong diagnostic potential for AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China.
- Miracle (Shenzhen) Biotechnology Co., Ltd., Shenzhen, Guangdong Province, China.
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
- Neurodegenerative Laboratory of Ministry of Education of the People's Republic of China, Beijing, China.
Zitieren
APA
Qin, Q., Xia, X., Zhang, X., Yang, S., Zhao, G., Su, C., & Tang, Y. (2026). Development of a serum-based microRNA panel for Alzheimer's disease diagnosis. Journal of Translational Internal Medicine, 14(3), 456-469. https://doi.org/10.1515/jtim-2026-0038
Vancouver
Qin Q, Xia X, Zhang X, Yang S, Zhao G, Su C, et al. Development of a serum-based microRNA panel for Alzheimer's disease diagnosis. Journal of Translational Internal Medicine. 2026;14(3):456-469. doi:10.1515/jtim-2026-0038
BibTeX
@article{Qin2026,
author = {Qin, Qi and Xia, Xinyi and Zhang, Xinyu and Yang, Songtao and Zhao, Guodong and Su, Chang and Tang, Yi},
title = {Development of a serum-based microRNA panel for Alzheimer's disease diagnosis},
journal = {Journal of Translational Internal Medicine},
year = {2026},
volume = {14},
number = {3},
pages = {456--469},
doi = {10.1515/jtim-2026-0038}
}
EUVIMED